Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 7.768
Filter
1.
Georgian Med News ; (349): 98-102, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38963211

ABSTRACT

We report a severe case of a 25-year-old girl presented with complaints of weakness, diarrhoea, vomiting, pain in abdomen and hypotension at Infectious Diseases and Clinical Immunology Research Center. From history on 25 February till 29 February she was in India and on 1 march this problem started with watery diarrhoea followed by vomiting. She ate pizza with mushroom following which her condition worsened. Stool culture revealed salmonella nontyphi (nonthyphodal Salmonella)and this is leading cause for gastroenteritis, bacteremia and affects several other bodily system. Her condition deteriorated due to the development of ARDS (acute respiratory distress syndrome) and for this she was on mechanical ventilation. Vitec machine was performed, which identified Salmonella typhi murium. Our goal is to manage and treat this patient well by early diagnosis. She was given ceftriaxone, iv fluids and symptomatic treatment but due to resistance meropenem was started and the patient's condition improved. From serology there was no evidence of immunocompromised state so being a severe case of immunocompetent patient this case reflects the importance of timely diagnosis and management together with food safety practices in population. On follow up she was stable and discharged after 3 weeks. Future research studies need to be continued regarding newer strains, effective treatment strategies and diagnostics to prevent morbidity and mortality.


Subject(s)
Salmonella Infections , Humans , Female , Adult , Salmonella Infections/diagnosis , Salmonella Infections/drug therapy , Salmonella Infections/microbiology , Salmonella Infections/complications , Ceftriaxone/therapeutic use , Anti-Bacterial Agents/therapeutic use , Respiratory Distress Syndrome/microbiology , Respiratory Distress Syndrome/etiology , Multiple Organ Failure/microbiology , Multiple Organ Failure/etiology , Salmonella/isolation & purification , Meropenem/therapeutic use , Salmonella typhi/isolation & purification , Salmonella typhi/pathogenicity , Diarrhea/microbiology
2.
Ghana Med J ; 58(1): 86-90, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38957275

ABSTRACT

Objective: This study aims to examine the frequency of Salmonella Paratyphi found in blood cultures and evaluate the antibiotic susceptibility pattern of Salmonella isolates to different antibiotics. Additionally, the study aims to assess the paradigm shift in the trend of enteric fever caused by Salmonella Typhi (S. Typhi) to Salmonella Paratyphi(S. Paratyphi) . Study Design: Retrospective study. Participant: The study enrolled patients aged 12 years and above diagnosed with enteric fever (positive blood culture) and admitted to Peelamedu Samanaidu Govindasamy Naidu (PSG) Hospital. Interventions: The study analyzed demographic and antibiotic susceptibility profiles of Salmonella isolates collected from 106 enteric fever patients in the hospital between 2010 and 2022. The susceptibility profiles of Salmonella isolates to multiple antibiotics were assessed. Results: There were 106 participants, and 95 (89.62%) of them had enteric fever linked to Salmonella Typhi, while only 11 (10.38%) had enteric fever linked to Salmonella Paratyphi A. From 2010 to 2022, the study discovered a general decline in the prevalence of enteric fever caused by Salmonella species. But between 2014 and 2022, the incidence of enteric fever linked to S. Typhi rapidly increased. Azithromycin (100% , n = 106) and ceftriaxone (99% , n = 105) were highly effective against the Salmonella isolates, whereas nalidixic acid was resisted by 3 isolates (4.72%, n = 3). Conclusion: The study observed a higher incidence of Salmonella Typhi in comparison to Paratyphi A and a greater susceptibility of males to enteric fever. Funding: None declared.


Subject(s)
Anti-Bacterial Agents , Microbial Sensitivity Tests , Salmonella paratyphi A , Salmonella typhi , Typhoid Fever , Humans , Male , Female , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Typhoid Fever/epidemiology , Typhoid Fever/microbiology , Typhoid Fever/drug therapy , Retrospective Studies , Salmonella typhi/drug effects , Salmonella typhi/isolation & purification , Salmonella paratyphi A/drug effects , Salmonella paratyphi A/isolation & purification , Adult , Adolescent , Child , Middle Aged , Young Adult , Paratyphoid Fever/epidemiology , Paratyphoid Fever/microbiology , Paratyphoid Fever/drug therapy , Incidence , Drug Resistance, Bacterial , Azithromycin/therapeutic use , Azithromycin/pharmacology , Ceftriaxone/therapeutic use , Ceftriaxone/pharmacology , Aged , Prevalence
3.
Aust J Gen Pract ; 53(7): 499-503, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38959520

ABSTRACT

BACKGROUND AND OBJECTIVES: There were 82.4 million new gonorrhoea cases worldwide in 2020. Dual treatment with ceftriaxone or cefixime and azithromycin or doxycycline is currently recommended for gonorrhoea in Indonesia. However, reduced susceptibility and resistance to cephalosporins and azithromycin are increasing. We evaluated the susceptibility pattern of Neisseria gonorrhoeae to cefixime, ceftriaxone, azithromycin and doxycycline. METHOD: N. gonorrhoeae isolates were obtained from 19 male participants with clinically and laboratory-confirmed gonorrhoea. Antibiotic susceptibility testing was conducted by disc diffusion and interpreted according to Clinical and Laboratory Standards Institute and Centers for Disease Control and Prevention criteria. RESULTS: Reduced susceptibility or resistance was observed against doxycycline in 19 isolates (100%), cefixime in six (31.6%), ceftriaxone in three (15.8%) and azithromycin in zero (0%) isolates. DISCUSSION: A dual treatment regimen with ceftriaxone and azithromycin can still be recommended as first-line therapy for gonorrhoea in Indonesia. Antibiotic susceptibility surveillance of N. gonorrhoeae should be routinely conducted.


Subject(s)
Anti-Bacterial Agents , Azithromycin , Ceftriaxone , Doxycycline , Gonorrhea , Microbial Sensitivity Tests , Neisseria gonorrhoeae , Humans , Indonesia , Neisseria gonorrhoeae/drug effects , Anti-Bacterial Agents/therapeutic use , Anti-Bacterial Agents/pharmacology , Gonorrhea/drug therapy , Male , Microbial Sensitivity Tests/methods , Azithromycin/therapeutic use , Doxycycline/therapeutic use , Ceftriaxone/therapeutic use , Ceftriaxone/pharmacology , Adult , Cefixime/therapeutic use , Cefixime/pharmacology , Primary Health Care/statistics & numerical data , Drug Resistance, Bacterial/drug effects , Drug Therapy, Combination/methods
4.
J Investig Med High Impact Case Rep ; 12: 23247096241261508, 2024.
Article in English | MEDLINE | ID: mdl-38877708

ABSTRACT

Nocardia pyomyositis in immunocompetent patients is a rare occurrence. The diagnosis may be missed or delayed with the risk of progressive infection and suboptimal or inappropriate treatment. We present the case of a 48-year-old immunocompetent firefighter diagnosed with pyomyositis caused by Nocardia brasiliensis acquired by direct skin inoculation from gardening activity. The patient developed a painful swelling on his right forearm that rapidly progressed proximally and deeper into the underlying muscle layer. Ultrasound imaging of his right forearm showed a 7-mm subcutaneous fluid collection with surrounding edema. Microbiologic analysis of the draining pus was confirmed to be N brasiliensis by Matrix-Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF) Mass Spectrometry. After incision and drainage deep to the muscle layer to evacuate the abscess and a few ineffective antibiotic options, the patient was treated with intravenous ceftriaxone and oral linezolid for 6 weeks. He was then de-escalated to oral moxifloxacin for an additional 4 months to complete a total antibiotic treatment duration of 6 months. The wound healed satisfactorily and was completely closed by the fourth month of antibiotic therapy. Six months after discontinuation of antibiotics, the patient continued to do well with complete resolution of the infection. In this article, we discussed the risk factors for Nocardia in immunocompetent settings, the occupational risks for Nocardia in our index patient, and the challenges encountered with diagnosis and treatment. Nocardia should be included in the differential diagnosis of cutaneous infections, particularly if there is no improvement of "cellulitis" with traditional antimicrobial regimens and the infection extends into the deeper muscle tissues.


Subject(s)
Anti-Bacterial Agents , Gardening , Immunocompetence , Nocardia Infections , Nocardia , Pyomyositis , Humans , Male , Middle Aged , Nocardia Infections/diagnosis , Nocardia Infections/drug therapy , Nocardia/isolation & purification , Anti-Bacterial Agents/therapeutic use , Pyomyositis/drug therapy , Pyomyositis/diagnosis , Pyomyositis/microbiology , Ceftriaxone/therapeutic use , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization , Drainage , Moxifloxacin/therapeutic use , Moxifloxacin/administration & dosage , Linezolid/therapeutic use
5.
P R Health Sci J ; 43(2): 68-72, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38860959

ABSTRACT

OBJECTIVE: Monitoring the susceptibility patterns of Neisseria gonorrhoeae is essential for the continuing compliance with current treatment recommendations. Puerto Rico conducts susceptibility tests on N. gonorrhoeae; however, trends on antimicrobial resistance in the island have not been reported since the mid 80's. METHODS: We performed a secondary analysis of a national data repository on the antimicrobial susceptibility of N. gonorrhoeae isolates between 2012 and 2017; a period of time when the CDC recommended a single dose of ceftriaxone and azithromycin for the treatment of uncomplicated gonorrhea. Data on susceptibility to eight antibiotics using the standard disk diffusion method was obtained for 30.0% (84/276) of the samples collected from the Sexually Transmitted Disease clinics in Puerto Rico. We also performed patient demographic analyses linked to resistance. RESULTS: Rates of resistance to ceftriaxone and azithromycin were 0% and 4.0% (2/50), respectively. The percentage of isolates resistant to antimicrobials no longer recommended in Puerto Rico, such as tetracycline, ciprofloxacin, and penicillin, was 86.0% (43/50), 76.0% (38/50), and 38.0% (19/50), respectively. Prevalence of resistant N. gonorrhoeae was higher among men who have sex with men, MSM (79%, 37/47). DISCUSSION: Lack of resistance to ceftriaxone and slow emergence of azithromycin resistance was identified from 2012-2017. It is imperative to continue the surveillance for emerging patterns of resistance, especially for ceftriaxone, as it is part of the current treatment guidelines. Therefore, protocols for culture based surveillance, including sample transport and processing, should be strengthened to ensure quality assured epidemiology of gonococcal resistance in Puerto Rico.


Subject(s)
Anti-Bacterial Agents , Drug Resistance, Bacterial , Gonorrhea , Microbial Sensitivity Tests , Neisseria gonorrhoeae , Puerto Rico , Neisseria gonorrhoeae/drug effects , Neisseria gonorrhoeae/isolation & purification , Humans , Male , Gonorrhea/drug therapy , Gonorrhea/microbiology , Gonorrhea/epidemiology , Female , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/administration & dosage , Adult , Young Adult , Azithromycin/pharmacology , Azithromycin/administration & dosage , Ceftriaxone/pharmacology , Adolescent , Middle Aged
6.
Wiad Lek ; 77(3): 608-612, 2024.
Article in English | MEDLINE | ID: mdl-38691808

ABSTRACT

A case report of Jarisch-Herxheimer (JHR) reaction on a 10th day of Leptospirosis caused by Leptospira Pomona. JHR occurs as a complication of an antibiotic treatment of various spirochetes and may lead to respiratory distress syndrome, renal failure, hepatic insufficiency, and multiple organ failure. This case represents a skin and cardio-vascular form of JHR with no lung involvement. The patient was treated with benzylpenicillin and low dexamethasone doses for 5th day of the disease with a shift to ceftriaxone and high doses of methylprednisolone. The fastest diagnosis of a sporadic zoonotic disease, early start of antibiotic therapy, and adequate doses of corticosteroids are key to the successful treatment of leptospirosis.


Subject(s)
Anti-Bacterial Agents , Leptospirosis , Humans , Male , Anti-Bacterial Agents/therapeutic use , Anti-Bacterial Agents/adverse effects , Ceftriaxone/therapeutic use , Ceftriaxone/adverse effects , Dexamethasone/therapeutic use , Dexamethasone/adverse effects , Leptospira/isolation & purification , Leptospirosis/drug therapy , Leptospirosis/complications , Methylprednisolone/therapeutic use , Methylprednisolone/administration & dosage , Aged
7.
J Antimicrob Chemother ; 79(7): 1619-1627, 2024 Jul 01.
Article in English | MEDLINE | ID: mdl-38804149

ABSTRACT

OBJECTIVES: The quality of amoxicillin capsules, ceftriaxone for injection, and ciprofloxacin tablets was evaluated to determine whether there is any difference in quality when comparing the country of origin. This was undertaken because it has been claimed that antibiotics manufactured in Europe are of superior quality to those originating from Africa or Asia. METHODS: Samples of amoxicillin capsules, ceftriaxone for injection, and ciprofloxacin tablets were collected from three randomly selected wholesale pharmacies in each city, namely Arusha, Dar es Salaam and Mwanza, Tanzania. The collected samples of collected brands were subjected to quality control testing as per their respective pharmacopoeial monographs. Amoxil 250 mg capsules (Glaxo Wellcome, Mayenne, France), Rocephin (Roche, Switzerland) and Cipro-Denk 500 (Allphamed Pharbil Arzneimittel GmbH, Gottingen, Germany) were used as reference brands for the other generic brands of amoxicillin, ceftriaxone and ciprofloxacin, respectively. RESULTS: A total of 31 brands (10 different brands of amoxicillin capsules, 9 of ceftriaxone sodium injections, and 12 of ciprofloxacin tablets) were collected from the targeted regions and subjected to quality control testing. All samples of collected brands complied with the requirements of their respective pharmacopoeial monographs. CONCLUSIONS: There was no significant difference in quality between brands of amoxicillin capsules, ceftriaxone for injection, and ciprofloxacin tablets manufactured in Africa and Asia against those manufactured in Europe in terms of compliance with the respective pharmacopoeial monographs.


Subject(s)
Anti-Bacterial Agents , Ciprofloxacin , Quality Control , Tanzania , Anti-Bacterial Agents/analysis , Ciprofloxacin/analysis , Humans , Ceftriaxone/analysis , Ceftriaxone/chemistry , Amoxicillin/analysis , Amoxicillin/standards , Amoxicillin/chemistry , Tablets
9.
Microbiome ; 12(1): 80, 2024 May 07.
Article in English | MEDLINE | ID: mdl-38715137

ABSTRACT

BACKGROUND: Antibiotic exposure can occur in medical settings and from environmental sources. Long-term effects of brief antibiotic exposure in early life are largely unknown. RESULTS: Post a short-term treatment by ceftriaxone to C57BL/6 mice in early life, a 14-month observation was performed using 16S rRNA gene-sequencing technique, metabolomics analysis, and metagenomics analysis on the effects of ceftriaxone exposure. Firstly, the results showed that antibiotic pre-treatment significantly disturbed gut microbial α and ß diversities (P < 0.05). Both Chao1 indices and Shannon indices manifested recovery trends over time, but they didn't entirely recover to the baseline of control throughout the experiment. Secondly, antibiotic pre-treatment reduced the complexity of gut molecular ecological networks (MENs). Various network parameters were affected and manifested recovery trends over time with different degrees, such as nodes (P < 0.001, R2 = 0.6563), links (P < 0.01, R2 = 0.4543), number of modules (P = 0.0672, R2 = 0.2523), relative modularity (P = 0.6714, R2 = 0.0155), number of keystones (P = 0.1003, R2 = 0.2090), robustness_random (P = 0.79, R2 = 0.0063), and vulnerability (P = 0.0528, R2 = 0.28). The network parameters didn't entirely recover. Antibiotic exposure obviously reduced the number of key species in gut MENs. Interestingly, new keystones appeared during the recovery process of network complexity. Changes in network stability might be caused by variations in network complexity, which supports the ecological theory that complexity begets stability. Besides, the metabolism profiles of the antibiotic group and control were significantly different. Correlation analysis showed that antibiotic-induced differences in gut microbial metabolism were related to MEN changes. Antibiotic exposure also caused long-term effects on gut microbial functional networks in mice. CONCLUSIONS: These results suggest that short-term antibiotic exposure in early life will cause long-term negative impacts on gut microbial diversity, MENs, and microbial metabolism. Therefore, great concern should be raised about children's brief exposure to antibiotics if the results observed in mice are applicable to humans. Video Abstract.


Subject(s)
Anti-Bacterial Agents , Bacteria , Gastrointestinal Microbiome , Mice, Inbred C57BL , RNA, Ribosomal, 16S , Gastrointestinal Microbiome/drug effects , Animals , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/adverse effects , Mice , RNA, Ribosomal, 16S/genetics , Bacteria/genetics , Bacteria/classification , Bacteria/metabolism , Bacteria/drug effects , Ceftriaxone/pharmacology , Metagenomics/methods , Male , Metabolomics , Feces/microbiology
10.
N Z Med J ; 137(1594): 31-42, 2024 May 03.
Article in English | MEDLINE | ID: mdl-38696830

ABSTRACT

AIM: Our antimicrobial guidelines (AGs) were changed in 2021 to recommend once-daily ceftriaxone in place of three-times-daily cefuroxime as preferred cephalosporin. This analysis sought to assess the effects of this on incidence of Clostridioides difficile infection (CDI), third-generation cephalosporin-resistant Enterobacterales (3GCR-E) and resource utilisation. METHOD: Before and after analysis of 30-day CDI and 3GCR-E incidence following receipt of cefuroxime/ceftriaxone pre- and post-AG change. Total nursing time and waste production relating to cefuroxime/ceftriaxone delivery were calculated pre- and post-change. RESULTS: CDI incidence was 0.6% pre- and 1.0% post-change (adjusted odds ratio [aOR] 1.44, p=0.07) and 3GCR-E incidence 3.5% and 3.1% (aOR 0.90, p=0.33). Mean per-quarter estimated nursing administration time decreased from 2,065 to 1,163 hours (902 nurse-hour reduction) and antibiotic-related waste generation from 1,131kg to 748kg (383kg reduction). Overall days of therapy per-quarter of cefuroxime/ceftriaxone were unchanged between periods. CONCLUSION: This simplification of our AG from a three-times-daily to a once-daily antibiotic resulted in considerable savings for our hospital (roughly 1.7 full-time equivalent nurses and over a tonne of waste yearly), with no significant increases in CDI or 3GCR-E. The impact of dosing schedules on non-antibiotic-spectrum factors, such as nursing time and resource usage, is worthy of consideration when designing AGs.


Subject(s)
Anti-Bacterial Agents , Antimicrobial Stewardship , Ceftriaxone , Cefuroxime , Humans , Cefuroxime/therapeutic use , Cefuroxime/administration & dosage , Anti-Bacterial Agents/therapeutic use , Anti-Bacterial Agents/administration & dosage , Ceftriaxone/therapeutic use , Ceftriaxone/administration & dosage , Male , Female , Clostridium Infections/drug therapy , Clostridium Infections/epidemiology , Middle Aged , Incidence , Aged , Enterobacteriaceae Infections/drug therapy , Enterobacteriaceae Infections/epidemiology , Practice Guidelines as Topic , Drug Administration Schedule
11.
PLoS One ; 19(5): e0302808, 2024.
Article in English | MEDLINE | ID: mdl-38696487

ABSTRACT

BACKGROUND: One of the largest problems facing the world today is the morbidity and mortality caused by antibiotic resistance in bacterial infections. A major factor in antimicrobial resistance (AMR) is the irrational use of antibiotics. The objective of this study was to assess the prescribing pattern and cost of antibiotics in two major governmental hospitals in the West Bank of Palestine. METHODS: A retrospective cohort study was conducted on 428 inpatient prescriptions containing antibiotics from two major governmental hospitals, they were evaluated by some drug use indicators. The cost of antibiotics in these prescriptions was calculated based on the local cost. Descriptive statistics were performed using IBM-SPSS version 21. RESULTS: The mean ± SD number of drugs per prescription (NDPP) was 6.72 ± 4.37. Of these medicines, 38.9% were antibiotics. The mean ± SD number of antibiotics per prescription (NAPP) was 2.61 ± 1.54. The average ± SD cost per prescription (CPP) was 392 ± 744 USD. The average ± SD antibiotic cost per prescription (ACPP) was 276 ± 553 USD. The most commonly prescribed antibiotics were ceftriaxone (52.8%), metronidazole (24.8%), and vancomycin (21.0%). About 19% of the antibiotics were prescribed for intra-abdominal infections; followed by 16% used as prophylactics to prevent infections. Almost all antibiotics prescribed were administered intravenously (IV) 94.63%. In general, the average duration of antibiotic therapy was 7.33 ± 8.19 days. The study indicated that the number of antibiotics per prescription was statistically different between the hospitals (p = 0.022), and it was also affected by other variables like the diagnosis (p = 0.006), the duration of hospitalization (p < 0.001), and the NDPP (p < 0.001). The most commonly prescribed antibiotics and the cost of antibiotics per prescription were significantly different between the two hospitals (p < 0.001); The cost was much higher in the Palestinian Medical Complex. CONCLUSION: The practice of prescribing antibiotics in Palestine's public hospitals may be unnecessary and expensive. This has to be improved through education, adherence to recommendations, yearly immunization, and stewardship programs; intra-abdominal infections were the most commonly seen infection in inpatients and ceftriaxone was the most frequently administered antibiotic.


Subject(s)
Anti-Bacterial Agents , Practice Patterns, Physicians' , Humans , Anti-Bacterial Agents/therapeutic use , Anti-Bacterial Agents/economics , Retrospective Studies , Female , Male , Practice Patterns, Physicians'/statistics & numerical data , Practice Patterns, Physicians'/economics , Middle East , Adult , Middle Aged , Hospitalization/economics , Drug Prescriptions/economics , Drug Prescriptions/statistics & numerical data , Ceftriaxone/therapeutic use , Ceftriaxone/economics , Drug Costs , Aged
12.
Diagn Microbiol Infect Dis ; 109(3): 116332, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38692203

ABSTRACT

We report a case of septic arthritis in a 43-year-old female patient. Despite initial treatment with ceftriaxone for Nontyphoidal Salmonella based on blood and joint fluid culture results, the shoulder joint pain worsened. Suspected systemic lupus erythematosus associated synovitis did not respond to immunosuppressive therapy including methylprednisolone, hydroxychloroquine and methotrexate. Subsequent radiograph revealed a shoulder joint abscess, leading to arthroscopic joint debridement. Ceftriaxone was administered post-operatively until analgesic efficacy was attained. This case highlights the significance of accurate diagnosis and appropriate treatment for nontyphoidal Salmonella septic arthritis.


Subject(s)
Anti-Bacterial Agents , Arthritis, Infectious , Lupus Erythematosus, Systemic , Salmonella Infections , Humans , Female , Arthritis, Infectious/microbiology , Arthritis, Infectious/drug therapy , Arthritis, Infectious/diagnosis , Adult , Lupus Erythematosus, Systemic/complications , Salmonella Infections/microbiology , Salmonella Infections/diagnosis , Salmonella Infections/drug therapy , Salmonella Infections/complications , Anti-Bacterial Agents/therapeutic use , Ceftriaxone/therapeutic use , Treatment Outcome , Debridement , Shoulder Joint/microbiology , Shoulder Joint/surgery , Salmonella/isolation & purification
13.
J Emerg Med ; 66(5): e632-e641, 2024 May.
Article in English | MEDLINE | ID: mdl-38704306

ABSTRACT

BACKGROUND: There is a lack of evidence-based guidelines for the administration methods of ceftriaxone in emergency departments (EDs), resulting in the reliance on individual institutional protocols for decision-making. OBJECTIVE: This study was performed to compare the effects of administering ceftriaxone via intravenous push (IVP) and intravenous piggyback (IVPB) on 28-day mortality in patients with sepsis. METHODS: This was a retrospective study of patients aged 18 years or older with sepsis or septic shock who visited an ED and were treated with ceftriaxone as an initial antibiotic between March 2010 and February 2019. Patients were divided into the IVP group and the IVPB group based on the administration method. The primary outcome was 28-day mortality, and multivariable Cox proportional hazards regression analysis was performed to evaluate the relationship between antibiotic administration methods and 28-day mortality. RESULTS: During the study period, a total of 939 patients were included in the final analysis, and the overall mortality rate was 12.2%. The antibiotic administration time was significantly lower in the IVP group than in the IVPB group, and the rates of antibiotic administration within 1 h and within 3 h were higher in the IVP group than in the IVPB group (p < 0.05). However, there was no significant difference in 28-day mortality between the two groups (hazard ratio 1.07, 95% confidence interval 0.69-1.65). CONCLUSIONS: IVP administration of ceftriaxone reduced the time of antibiotic administration compared with IVPB, but there was no difference in 28-day mortality.


Subject(s)
Administration, Intravenous , Anti-Bacterial Agents , Ceftriaxone , Emergency Service, Hospital , Sepsis , Humans , Ceftriaxone/therapeutic use , Ceftriaxone/administration & dosage , Retrospective Studies , Male , Female , Anti-Bacterial Agents/therapeutic use , Anti-Bacterial Agents/administration & dosage , Sepsis/drug therapy , Sepsis/mortality , Middle Aged , Aged , Emergency Service, Hospital/organization & administration , Proportional Hazards Models , Aged, 80 and over , Adult
14.
Sex Transm Infect ; 100(4): 226-230, 2024 May 31.
Article in English | MEDLINE | ID: mdl-38702191

ABSTRACT

OBJECTIVES: Antibiotic resistance in gonorrhoea is of significant public health concern with the emergence of resistance to last-line therapies such as ceftriaxone. Despite around half of Neisseria gonorrhoeae isolates tested in the UK being susceptible to ciprofloxacin, very little ciprofloxacin is used in clinical practice. Testing for the S91F mutation associated with ciprofloxacin resistance is now available in CE-marked assays and may reduce the requirement for ceftriaxone, but many patients are treated empirically, or as sexual contacts, which may limit any benefit. We describe the real-world impact of such testing on antimicrobial use and clinical outcomes in people found to have gonorrhoea in a large urban UK sexual health clinic. METHODS: Molecular ciprofloxacin resistance testing (ResistancePlus GC assay (SpeeDx)) was undertaken as an additional test after initial diagnosis (m2000 Realtime CT/NG assay (Abbott Molecular)) in those not already known to have had antimicrobial treatment. Data from a 6-month period (from March to September 2022) were analysed to determine treatment choice and treatment outcome. RESULTS: A total of 998 clinical samples tested positive for N. gonorrhoeae in 682 episodes of infection. Of the 560 (56%) samples eligible for resistance testing, 269 (48.0%) were reported as wild-type, 180 (32.1%) were predicted to be resistant, 63 (11.3%) had an indeterminate resistance profile, and in 48 (8.6%) samples, N. gonorrhoeae was not detected. Ciprofloxacin was prescribed in 172 (75%) of 228 episodes in which the wild-type strain was detected. Four (2%) of those treated with ciprofloxacin had a positive test-of-cure sample by NAAT, with no reinfection risk. All four had ciprofloxacin-susceptible infection by phenotypic antimicrobial susceptibility testing. CONCLUSIONS: In routine practice in a large UK clinic, molecular ciprofloxacin resistance testing led to a significant shift in antibiotic use, reducing use of ceftriaxone. Testing can be targeted to reduce unnecessary additional testing. Longer term impact on antimicrobial resistance requires ongoing surveillance.


Subject(s)
Anti-Bacterial Agents , Ciprofloxacin , Drug Resistance, Bacterial , Gonorrhea , Microbial Sensitivity Tests , Neisseria gonorrhoeae , Humans , Ciprofloxacin/therapeutic use , Ciprofloxacin/pharmacology , Gonorrhea/drug therapy , Gonorrhea/diagnosis , Gonorrhea/microbiology , Neisseria gonorrhoeae/drug effects , Neisseria gonorrhoeae/genetics , Anti-Bacterial Agents/therapeutic use , Anti-Bacterial Agents/pharmacology , Drug Resistance, Bacterial/genetics , Male , Female , Adult , United Kingdom , Ceftriaxone/therapeutic use , Ceftriaxone/pharmacology , Mutation , Young Adult , Middle Aged
15.
J Antimicrob Chemother ; 79(6): 1456-1461, 2024 Jun 03.
Article in English | MEDLINE | ID: mdl-38708907

ABSTRACT

BACKGROUND: A small proportion of Escherichia coli and Klebsiella pneumoniae demonstrate in vitro non-susceptibility to piperacillin/tazobactam but retain susceptibility to ceftriaxone. Uncertainty remains regarding how best to treat these isolates. OBJECTIVES: We sought to compare clinical outcomes between patients with piperacillin/tazobactam-non-susceptible but ceftriaxone-susceptible E. coli or K. pneumoniae bloodstream infection receiving definitive therapy with ceftriaxone versus an alternative effective antibiotic. METHODS: We retrospectively identified patients with a positive blood culture for piperacillin/tazobactam-non-susceptible but ceftriaxone-susceptible E. coli or K. pneumoniae between 1 January 2013 and 31 December 2022. Patients were divided into one of two definitive treatment groups: ceftriaxone or alternative effective antibiotic. Our primary outcome was a composite of 90 day all-cause mortality, hospital readmission, or recurrence of infection. We used Cox proportional hazards models to compare time with the composite outcome between groups. RESULTS: Sixty-two patients were included in our analysis. Overall, median age was 63 years (IQR 49.5-71.0), the most common source of infection was intra-abdominal (25/62; 40.3%) and the median total duration of therapy was 12.0 days (IQR 9.0-16.8). A total of 9/22 (40.9%) patients in the ceftriaxone treatment group and 18/40 (45.0%) patients in the alternative effective antibiotic group met the composite endpoint. In an adjusted time-to-event analysis, there was no difference in the composite endpoint between groups (HR 0.67, 95% CI 0.30-1.50). The adjusted Bayesian posterior probability that the HR was less than or equal to 1 (i.e. ceftriaxone is as good or better than alternative therapy) was 85%. CONCLUSIONS: These findings suggest that ceftriaxone can be used to effectively treat bloodstream infections with E. coli or K. pneumoniae that are non-susceptible to piperacillin/tazobactam but susceptible to ceftriaxone.


Subject(s)
Anti-Bacterial Agents , Bacteremia , Ceftriaxone , Escherichia coli Infections , Escherichia coli , Klebsiella Infections , Klebsiella pneumoniae , Microbial Sensitivity Tests , Piperacillin, Tazobactam Drug Combination , Humans , Ceftriaxone/therapeutic use , Ceftriaxone/pharmacology , Klebsiella pneumoniae/drug effects , Klebsiella pneumoniae/isolation & purification , Middle Aged , Male , Female , Retrospective Studies , Aged , Anti-Bacterial Agents/therapeutic use , Anti-Bacterial Agents/pharmacology , Piperacillin, Tazobactam Drug Combination/therapeutic use , Piperacillin, Tazobactam Drug Combination/pharmacology , Escherichia coli/drug effects , Escherichia coli/isolation & purification , Bacteremia/drug therapy , Bacteremia/microbiology , Bacteremia/mortality , Klebsiella Infections/drug therapy , Klebsiella Infections/microbiology , Klebsiella Infections/mortality , Escherichia coli Infections/drug therapy , Escherichia coli Infections/microbiology , Treatment Outcome
16.
Pharm Res ; 41(5): 863-875, 2024 May.
Article in English | MEDLINE | ID: mdl-38605261

ABSTRACT

OBJECTIVE: This study aimed to improve the efficiency of pharmacotherapy for CNS diseases by optimizing the ability of drug molecules to penetrate the Blood-Brain Barrier (BBB). METHODS: We established qualitative and quantitative databases of the ADME properties of drugs and derived characteristic features of compounds with efficient BBB penetration. Using these insights, we developed four machine learning models to predict a drug's BBB permeability by assessing ADME properties and molecular topology. We then validated the models using the B3DB database. For acyclovir and ceftriaxone, we modified the Hydrogen Bond Donors and Acceptors, and evaluated the BBB permeability using the predictive model. RESULTS: The machine learning models performed well in predicting BBB permeability on both internal and external validation sets. Reducing the number of Hydrogen Bond Donors and Acceptors generally improves BBB permeability. Modification only enhanced BBB penetration in the case of acyclovir and not ceftriaxone. CONCLUSIONS: The machine learning models developed can accurately predict BBB permeability, and many drug molecules are likely to have increased BBB penetration if the number of Hydrogen Bond Donors and Acceptors are reduced. These findings suggest that molecular modifications can enhance the efficacy of CNS drugs and provide practical strategies for drug design and development. This is particularly relevant for improving drug penetration of the BBB.


Subject(s)
Acyclovir , Blood-Brain Barrier , Machine Learning , Permeability , Blood-Brain Barrier/metabolism , Humans , Acyclovir/pharmacokinetics , Hydrogen Bonding , Ceftriaxone/pharmacokinetics , Central Nervous System Agents/pharmacokinetics , Central Nervous System Agents/chemistry , Central Nervous System Agents/metabolism , Drug Design
17.
J Korean Med Sci ; 39(15): e136, 2024 Apr 22.
Article in English | MEDLINE | ID: mdl-38651222

ABSTRACT

BACKGROUND: Haemophilus influenzae is a frequently encountered pathogen responsible for respiratory tract infections in children. Following the detection of ceftriaxone-resistant H. influenzae at our institution, we aimed to investigate the resistance mechanisms of ceftriaxone in H. influenzae, with a particular focus on alterations in penicillin-binding protein 3 (PBP3) and ß-lactamase production. METHODS: Among H. influenzae isolates collected at Asan Medical Center Children's Hospital from March 2014 to April 2019, ceftriaxone-resistant strains by the disk-diffusion test were included. Ceftriaxone minimum inhibitory concentrations (MICs) were determined using the E-test according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines. The presence of ß-lactamase was assessed through cefinase test and TEM-1/ROB-1 polymerase chain reaction (PCR). PBP3 alterations were explored via ftsI gene sequencing. RESULTS: Out of the 68 collected strains, 21 exhibited resistance to ceftriaxone in disk diffusion tests. Two strains were excluded due to failed subculture. Among 19 ceftriaxone-resistant H. influenzae isolates, eighteen were non-typeable H. influenzae, and twelve were positive for TEM-1 PCR. Isolates were classified into groups II (harboring only N526K, n = 3), III (N526K+S385T, n = 2), III+ (S385T+L389F+N526K, n = 11), and III-like+ (S385T+L389F+R517H, n = 3) according to the PBP3 alteration pattern. With a median ceftriaxone MIC of 0.190 mg/L (range, 0.008-0.750), the median ceftriaxone MIC was the highest in group III-like+ (0.250 mg/L), followed by groups III+ (0.190 mg/L), III (0.158 mg/L), and II (0.012 mg/L). All three strains belonging to group II, which did not harbor the S385T substitution, had ceftriaxone MICs of ≤ 0.125 mg/L. CONCLUSION: The emergence of ceftriaxone-resistant H. influenzae with ceftriaxone MIC values of up to 0.75 mg/L was observed even in children in South Korea, with most associated with S385T and L389F substitutions. The N526K mutation alone does not significantly impact ceftriaxone resistance. Further large-scale studies are essential to investigate changes in antibiotic resistance patterns and factors influencing antibiotic resistance in H. influenzae isolated from pediatric patients in Korea.


Subject(s)
Anti-Bacterial Agents , Ceftriaxone , Haemophilus Infections , Haemophilus influenzae , Microbial Sensitivity Tests , beta-Lactamases , Ceftriaxone/pharmacology , Haemophilus influenzae/drug effects , Haemophilus influenzae/isolation & purification , Haemophilus influenzae/genetics , Humans , Anti-Bacterial Agents/pharmacology , Republic of Korea , beta-Lactamases/genetics , beta-Lactamases/metabolism , Child , Haemophilus Infections/microbiology , Haemophilus Infections/drug therapy , Penicillin-Binding Proteins/genetics , Child, Preschool , Drug Resistance, Bacterial , Infant , Female , Male , Bacterial Proteins/genetics , Bacterial Proteins/metabolism
18.
Front Cell Infect Microbiol ; 14: 1353433, 2024.
Article in English | MEDLINE | ID: mdl-38558854

ABSTRACT

Objective: To analyze the clinical epidemiological characteristics including clinical features, disease prognosis of pneumococcal meningitis (PM), and drug sensitivity of S. pneumoniae isolates in Chinese children. Methods: A retrospective analysis was performed on the clinical, laboratory microbiological data of 160 hospitalized children less than 15 years of age with PM from January 2019 to December 2020 in 33 tertiary hospitals in China. Results: A total of 160 PM patients were diagnosed, including 103 males and 57 females The onset age was 15 days to 15 years old, and the median age was 1 year and 3 months. There were 137 cases (85.6%) in the 3 months to <5 years age group, especially in the 3 months to <3 years age group (109 cases, 68.2%); S. pneumoniae was isolated from cerebrospinal fluid (CSF) culture in 95(35.6%), and 57(35.6%) in blood culture. The positive rates of S. pneumoniae detection by CSF metagenomic next-generation sequencing (mNGS)and antigen detection method were 40.2% (35/87) and 26.9% (21/78). Fifty-five cases (34.4%) had one or more predisposing factors of bacterial meningitis; and 113 cases (70.6%) had one or more extracranial infection diseases Fever (147, 91.9%) was the most common clinical symptom, followed by vomiting (61, 38.1%) and altered mental status (47,29.4%). Among 160 children with PM, the main intracranial imaging complications were subdural effusion and (or) empyema in 43 cases (26.9%), hydrocephalus in 24 cases (15.0%), cerebral abscess in 23 cases (14.4%), intracranial hemorrhage in 8 cases (5.0%), and other cerebrovascular diseases in 13 cases (8.1%) including encephalomalacia, cerebral infarction, and encephalatrophy. Subdural effusion and (or) empyema and hydrocephalus mainly occurred in children < 1 years old (90.7% (39/43) and 83.3% (20/24), respectively). 17 cases with PM (39.5%) had more than one intracranial imaging abnormality. S. pneumoniae isolates were completely sensitive to vancomycin (100.0%, 75/75), linezolid (100.0%,56/56), ertapenem (6/6); highly sensitive to levofloxacin (81.5%, 22/27), moxifloxacin (14/17), rifampicin (96.2%, 25/26), and chloramphenicol (91.3%, 21/23); moderately sensitive to cefotaxime (56.1%, 23/41), meropenem (51.1%, 23/45) and ceftriaxone (63.5, 33/52); less sensitive to penicillin (19.6%, 27/138) and clindamycin (1/19); completely resistant to erythromycin (100.0%, 31/31). The cure and improvement rate were 22.5% (36/160)and 66.3% (106/160), respectively. 18 cases (11.3%) had an adverse outcome, including 6 cases withdrawing treatment therapy, 5 cases unhealed, 5 cases died, and 2 recurrences. S. pneumoniae was completely susceptible to vancomycin (100.0%, 75/75), linezolid (100.0%, 56/56), and ertapenem (6/6); susceptible to cefotaxime, meropenem, and ceftriaxone in the order of 56.1% (23/41), 51.1% (23/45), and 63.5 (33/52); completely resistant to erythromycin (100.0%, 31/31). Conclusion: Pediatric PM is more common in children aged 3 months to < 3 years old. Intracranial complications mostly occur in children < 1 year of age with fever being the most common clinical manifestations and subdural effusion and (or) empyema and hydrocephalus being the most common complications, respectively. CSF non-culture methods can facilitate improving the detection rate of pathogenic bacteria. More than 10% of PM children had adverse outcomes. S. pneumoniae strains are susceptible to vancomycin, linezolid, ertapenem, levofloxacin, moxifloxacin, rifampicin, and chloramphenicol.


Subject(s)
Empyema , Hydrocephalus , Meningitis, Bacterial , Meningitis, Pneumococcal , Subdural Effusion , Adolescent , Child , Female , Humans , Infant , Male , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Cefotaxime , Ceftriaxone/therapeutic use , Chloramphenicol , Empyema/drug therapy , Ertapenem/therapeutic use , Erythromycin/therapeutic use , Hydrocephalus/drug therapy , Levofloxacin , Linezolid/therapeutic use , Meningitis, Bacterial/diagnosis , Meningitis, Pneumococcal/diagnosis , Meningitis, Pneumococcal/drug therapy , Meningitis, Pneumococcal/epidemiology , Meropenem/therapeutic use , Microbial Sensitivity Tests , Moxifloxacin/therapeutic use , Retrospective Studies , Rifampin , Subdural Effusion/drug therapy , Vancomycin , Infant, Newborn , Child, Preschool
19.
Sex Transm Infect ; 100(3): 173-180, 2024 Apr 18.
Article in English | MEDLINE | ID: mdl-38575313

ABSTRACT

OBJECTIVES: International travel combined with sex may contribute to dissemination of antimicrobial-resistant (AMR) Neisseria gonorrhoeae (Ng). To assess the role of travel in Ng strain susceptibility, we compared minimum inhibitory concentrations (MICs) for five antibiotics (ie, azithromycin, ceftriaxone, cefotaxime, cefixime and ciprofloxacin) in strains from clients with an exclusively Dutch sexual network and clients with an additional international sexual network. METHODS: From 2013 to 2019, we recorded recent residence of sexual partners of clients (and of their partners) with Ng at the Center for Sexual Health of Amsterdam. We categorised clients as having: (1) exclusively sexual partners residing in the Netherlands ('Dutch only') or (2) at least one partner residing outside the Netherlands. We categorised the country of residence of sexual partners by World Bank/EuroVoc regions. We analysed the difference of log-transformed MIC of Ng strains between categories using linear or hurdle regression for each antibiotic. RESULTS: We included 3367 gay and bisexual men who had sex with men (GBMSM), 516 women and 525 men who exclusively had sex with women (MSW) with Ng. Compared with GBMSM with a 'Dutch only' network, GBMSM with: (1) a Western European network had higher MICs for ceftriaxone (ß=0.19, 95% CI=0.08 to 0.29), cefotaxime (ß=0.19, 95% CI=0.08 to 0.31) and cefixime (ß=0.06, 95% CI=0.001 to 0.11); (2) a Southern European network had a higher MIC for cefixime (ß=0.10, 95% CI=0.02 to 0.17); and (3) a sub-Saharan African network had a lower MIC for ciprofloxacin (ß=-1.79, 95% CI=-2.84 to -0.74). In women and MSW, higher MICs were found for ceftriaxone in clients with a Latin American and Caribbean network (ß=0.26, 95% CI=0.02 to 0.51). CONCLUSIONS: For three cephalosporin antibiotics, we found Ng strains with slightly higher MICs in clients with partner(s) from Europe or Latin America and the Caribbean. International travel might contribute to the spread of Ng with lower susceptibility. More understanding of the emergence of AMR Ng is needed.


Subject(s)
Anti-Infective Agents , Gonorrhea , Sexual Health , Male , Female , Humans , Neisseria gonorrhoeae , Ceftriaxone/pharmacology , Ceftriaxone/therapeutic use , Cefixime/pharmacology , Gonorrhea/drug therapy , Gonorrhea/epidemiology , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Ciprofloxacin/pharmacology , Ciprofloxacin/therapeutic use , Azithromycin/pharmacology , Cefotaxime/pharmacology , Microbial Sensitivity Tests , Anti-Infective Agents/pharmacology , Drug Resistance, Bacterial
20.
Pol Merkur Lekarski ; 52(2): 216-225, 2024.
Article in English | MEDLINE | ID: mdl-38642358

ABSTRACT

OBJECTIVE: Aim: To study changes of dental biofilm microbiota composition during experimental opioid exposure, after its withdrawal and when using of complex drug correction.. PATIENTS AND METHODS: Materials and Methods: Microbiological studies (48 rats) included microscopic and bacteriological methods, as well as determination of antibiotic susceptibility of microbial isolates. Ceftriaxone and pentoxifylline were used to correction the changes. RESULTS: Results: The action of opioid for 10 weeks caused considerable changes in the microbiocenosis, which was illustrated by a significant increasing of the opportunistic pathogens quantitative indicators and the emergence of pathogenic microbiota. Changes in the microbiocenosis at 6 weeks of opioid exposure and after its withdrawal for 4 weeks were expressed in the appearance of pathogenic microbiota and the absence of significant differences in quantitative indicators of saprophytic and opportunistic microflora compared to similar indicators in animals with 10 weeks opioid exposure. This indicated a slow progression of dysbiotic changes and the inflammatory process in the oral cavity of rats. CONCLUSION: Conclusions: After 10 weeks of experiment with opioid administration for 6 weeks and the use of ceftriaxone and pentoxifylline on the background of 4-week opioid withdrawal, a significant reduction of quantitative indicators of opportunistic bacteria and elimination of pathogenic species of microorganisms was determined. The use of complex drug correction on the background of 10 weeks of opioid exposure led to a significant reduction in the quantitative indicators of opportunistic pathogens and contributed to the elimination of most pathogenic species of microbiota under the action of ceftriaxone.


Subject(s)
Microbiota , Pentoxifylline , Rats , Animals , Analgesics, Opioid/adverse effects , Ceftriaxone/pharmacology , Ceftriaxone/therapeutic use , Pharmaceutical Preparations , Pentoxifylline/pharmacology , Pentoxifylline/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...